NASDAQ:KNSAKiniksa Pharmaceuticals Stock Price, Forecast & News

Kiniksa Pharmaceuticals' stock was trading at $16.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KNSA stock has increased by 29.6% and is now trading at $20.87. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Kiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) announced its quarterly earnings data on Tuesday, April, 28th. The company reported ($0.48) EPS for the quarter, beating the Zacks' consensus estimate of ($0.63) by $0.15. View Kiniksa Pharmaceuticals' earnings history.

5 brokerages have issued 12-month price targets for Kiniksa Pharmaceuticals' shares. Their forecasts range from $18.00 to $35.00. On average, they anticipate Kiniksa Pharmaceuticals' share price to reach $25.50 in the next twelve months. This suggests a possible upside of 22.2% from the stock's current price. View analysts' price targets for Kiniksa Pharmaceuticals.

News headlines about KNSA stock have trended somewhat negative recently, InfoTrie reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kiniksa Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutKiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,610,000 shares, an increase of 15.5% from the April 30th total of 2,260,000 shares. Based on an average daily volume of 283,300 shares, the short-interest ratio is currently 9.2 days. Currently, 13.9% of the company's shares are short sold. View Kiniksa Pharmaceuticals' Current Options Chain.

Some companies that are related to Kiniksa Pharmaceuticals include Forty Seven (FTSV), Emergent Biosolutions (EBS), PPD (SDGR), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Global Blood Therapeutics (GBT), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Nektar Therapeutics (NKTR), ChemoCentryx (CCXI), GW Pharmaceuticals PLC- (GWPH), Biohaven Pharmaceutical (BHVN), Agios Pharmaceuticals (AGIO), BridgeBio Pharma (BBIO) and Blueprint Medicines (BPMC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Crispr Therapeutics (CRSP), Exelixis (EXEL), AbbVie (ABBV), Gilead Sciences (GILD), VBI Vaccines (VBIV), Vanda Pharmaceuticals (VNDA), Agile Therapeutics (AGRX), Clovis Oncology (CLVS), Dicerna Pharmaceuticals (DRNA) and ImmunoGen (IMGN).

(KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Kiniksa Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include ArrowMark Colorado Holdings LLC (2.29%), BlackRock Inc. (1.68%), Vivo Capital LLC (1.37%), Ikarian Capital LLC (0.65%), Spearhead Capital Advisors LLC (0.49%) and Nuveen Asset Management LLC (0.48%). Company insiders that own Kiniksa Pharmaceuticals stock include John F Paolini, Sanj K Patel and Thomas W Beetham. View institutional ownership trends for Kiniksa Pharmaceuticals.

KNSA stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Ghost Tree Capital LLC, Morgan Stanley, Squarepoint Ops LLC, Parametric Portfolio Associates LLC, BlackRock Inc., UBS Group AG, and State Street Corp. Company insiders that have sold Kiniksa Pharmaceuticals company stock in the last year include John F Paolini, Sanj K Patel, and Thomas W Beetham. View insider buying and selling activity for Kiniksa Pharmaceuticals.

KNSA stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Ikarian Capital LLC, Spearhead Capital Advisors LLC, Nuveen Asset Management LLC, Federated Hermes Inc., Atom Investors LP, Foresite Capital Management IV LLC, and Foresite Capital Management IV LLC. View insider buying and selling activity for Kiniksa Pharmaceuticals.

Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KNSA stock can currently be purchased for approximately $20.87.

Kiniksa Pharmaceuticals has a market capitalization of $1.16 billion. The company earns $-161,870,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Kiniksa Pharmaceuticals employs 111 workers across the globe.

The official website for Kiniksa Pharmaceuticals is www.kiniksa.com.

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 44-80-8189-6257 or via email at [email protected]